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Abstract 
Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID‑19 are 
poorly defined.
Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective 
observational study, which included a large cohort of blood cancer patients with laboratory‑confirmed SARS‑CoV‑2 
infection through PCR assays from March 1st 2020 to May 15th 2020.
Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of 
autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo‑SCT) (n = 65) from 41 hospitals in Spain. 
Median age of patients was 64 years (range 1–93.8). Recipients of ASCT and allo‑SCT showed lower mortality rates 
(17% and 18%, respectively) compared to non‑SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 
overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% con‑
fidence interval (CI) 1.2–3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6–5.2, p < 0.0001); 
ECOG 3–4 (OR, 2.56, 95% CI 1.4–4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3–6.1, p = 0.01); and a 
C‑reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7–6.4, p < 0.0001). In multivariate analysis of 216 patients with 
very severe COVID‑19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 
0.42, 95% CI 0.2–0.89 and OR 0.31, 95% CI 0.11–0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did 
not show significant improvement in OM (OR 0.64, 95% CI 0.37–1.1, P = 0.1).
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Background
The coronavirus infectious disease 2019 (COVID-
19) pandemic caused by the new zoonotic coronavi-
rus (SARS-CoV-2) is causing a massive impact globally. 
Mortality can be as high as 15% in elderly patients, and/
or in patients with comorbidities [1, 2]. Risk factors for 
COVID-19 severity and death include older age, diabetes, 
hypertension, or cardiac disease [1–4]. Prior experience 
with seasonal community-acquired respiratory virus 
(CARV) infections showed that, in immunocompro-
mised patients, these infections are notable for prolonged 
viral shedding, higher rates of pneumonia and mortal-
ity [5, 6]. Thus, it would be expected that COVID-19 be 
particularly life threatening in patients with hematologi-
cal malignancies. In fact, initial reports suggested that 
patients with cancer had an estimated two-fold increased 
risk of contracting SARS-CoV-2 than the general popu-
lation and, if infected, also had a higher risk of severe 
events [intensive care unit (ICU) admission, invasive 
ventilation, or death] compared to patients without can-
cer [7–9]. The outcomes of COVID-19 in patients with 
hematological disorders such as leukemia, lymphoma, 
myeloma and recipients of autologous (ASCT) or alloge-
neic hematopoietic stem cell transplantation (allo-SCT) 
are of utmost interest due to their high degree of humoral 
and cellular immunosuppression status. Recent studies 
have reported an overall COVID-19 related mortality of 
32 to 40% in hematological patients [10–14]. Future chal-
lenges include the identification of prognostic factors 
that could help in risk assessment and decision-making 
for effective supportive care and antiviral therapy or in 
cases of limited access to ICU.
The current study addresses the COVID-19 clinical 
course, outcome and risk factors for severe disease and 
mortality in a large series of patients with hematological 
disorders, including recipients of ASCT and allo-SCT.
Patients and methods
Study population
This is a retrospective multicenter cohort study of the 
Infectious Complications Subcommittee (GRUCINI) of 
the Spanish Hematopoietic Stem Cell Transplantation 
and Cell Therapy Group (GETH).
Inclusion criteria and data preparation
This series included patients (pediatric and adult) with 
PCR-documented SARS-CoV-2 infection diagnosed from 
March 1st 2020 to May 15th 2020 in 41 participating 
Spanish centers. The status of all patients (and thus the 
study database) was updated on May 21th 2020. During 
the study period, hematological patients from participat-
ing centers with COVID-19 were prospectively registered 
through REDcap on-line platform in the GETH database 
by completing an essential medical data form, and more 
detailed baseline and outcome data were retrospectively 
requested afterwards with follow-up forms. The infor-
mation collected included respiratory symptoms (rhi-
norrhea, cough, dyspnea, oxygen requirement, sinusitis, 
otitis, and fever), SARS-COV-2-related hospital admis-
sion, oxygen requirement, ICU admission, antiviral 
COVID-19 therapy given for at least 3 consecutive days, 
corticosteroid use and anti-cytokine therapy. The dose of 
corticosteroids was divided in 2 groups, ≤ or > 0.5 mg/kg/
day of methylprednisolone (or equivalent doses of pred-
nisone, dexamethasone or hydrocortisone). Details on 
the underlying disease and its treatment(s) were also cap-
tured (details not shown). Baseline laboratory variables, 
if available [absolute lymphocyte and neutrophil counts, 
C-reactive protein (CRP), IL6, ferritin and D-dimer lev-
els], were also requested at the time or within 3  days 
after SARS-CoV-2 detection. Detailed microbiological 
findings and radiological pulmonary patterns were also 
required for each episode.
Definitions
We classified COVID-19 stages according to the recent 
published staging proposal [15]. Briefly, stage 1 refers to 
early establishment of disease (symptomatic infection of 
the upper respiratory tract only, with or without fever 
and generalized malaise). In stage 1 we included patients 
reported as being asymptomatic by the registering phy-
sician, as well as patients with upper respiratory symp-
toms (rhinorrhea, sinusitis, otitis, or pharyngitis) and/or 
systemic symptoms (fever, diarrhea, nausea or vomiting, 
fatigue and myalgia) in the absence of lower respiratory 
tract disease (LRTD) symptoms and/or any indication of 
pulmonary infiltrates by radiology, either chest X-ray or 
computed tomography (CT) scan. Stage II was divided 
into IIA and IIB. Stage IIA refers to patients with LRTD 
with radiological proof of pulmonary involvement but 
without requirements for oxygen support to maintain 
an oxygen saturation > 92%. Stage IIB included patients 
meeting the IIA criteria but who required oxygen sup-
port (i.e., patients with acute respiratory failure). Finally, 
Conclusions: In most patients with hematological malignancies COVID‑19 mortality was directly driven by older age, 
disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high 
CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID‑19.
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we did not classify cases as stage III since we did not 
have sufficient inflammatory blood markers in all cases, 
which are required for upgrading a stage IIB to a stage 
III. Patients with stage IIB thus comprise all patients with 
severe COVID-19, while stage IIA can be considered to 
have moderate COVID-19. We considered very severe 
COVID-19 those who developed stage IIB and those who 
required ICU admission due to respiratory failure and/or 
hemodynamic instability.
Disease status at the time of SARS-CoV-2 detection 
was defined according to each specific disease’s revised 
criteria for leukemia, myeloproliferative neoplasm, mul-
tiple myeloma and lymphoma [16–18]. Performance sta-
tus at the time of COVID-19 was graded according to the 
Eastern Cooperative Oncology Group (ECOG) [19]. Car-
diomyopathy was defined by the patient’s medical history 
or when the left ventricular ejection fraction was < 50%, 
as were moderate to severe valvular disease, prior or cur-
rent history of coronary artery disease, or heart failure.
Technical and diagnostic considerations
Patients with URTD and/or LRTD symptoms underwent 
nasopharyngeal aspiration, nasopharyngeal swabs, or 
an induced sputum test, while BAL was performed very 
rarely and only in patients with negative PCR in the upper 
airway with radiology-proven LRTD and whenever an 
alternative diagnosis for the patient was deemed possible 
by each treating team. Most patients underwent weekly 
PCR test monitoring until negativity of SARS-CoV-2, 
especially when the patients improved and discharge was 
being considered, or for epidemiological reasons. The 
specific method used for performing the PCR was not 
captured. During this pandemic, GETH published on-
line recommendations on the diagnosis, management, 
testing and infectious control measures (available in the 
following website; https ://www.geth.es/).
Endpoints and statistical analysis
The primary objective of the study was to describe clini-
cal characteristics of COVID-19 in onco-hematological 
patients. We also analyzed potential risk factors (RFs) 
for the development of severe COVID-19 (stage IIB) and 
day 45 mortality after SARS-CoV-2 detection. Lastly, we 
explored the effect of antiviral and anti-cytokine therapy 
on mortality in patients with very severe COVID-19.
The main characteristics of patients were reported 
by descriptive statistics on the total of the available 
information. Median and range were used for continu-
ous variables, while absolute and percentage frequen-
cies were used for categorical variables. Univariate and 
multivariate analyses of clinical, laboratory and thera-
peutic variables associated with outcomes were calcu-
lated using logistic regression models. For multivariate 
analysis, only variables with parameter estimates show-
ing a p value ≤ 0.10 in the univariate analysis were finally 
included. Two-sided exact P values were reported and 
p values ≤ 0.05 were considered statistically significant. 
COVID-19 related mortality according to different clini-
cal and biological variables was estimated from time of 
SARS-CoV-2 detection using Kaplan–Meier curves and 
univariate comparisons were made with the log-rank test. 
All the analyses were performed using the statistical soft-
ware SPSS v. 20.
Results
Patient characteristics
Overall, 388 pediatric and adult patients with hema-
tological malignancies were initially registered. How-
ever, 21 cases were excluded due to negative results for 
SARS-CoV-2 PCR testing, irrespective of being clas-
sified as “probable COVID-19” by their hospital or 
regional epidemiologists based on a compatible clinical 
presentation and the large numbers of infections in the 
community. Thus, the study includes 367 patients with 
laboratory-confirmed SARS-CoV-2. Patient and disease 
characteristics according to whether they received or not 
a hematopoietic stem cell transplant (ASCT or allo-SCT) 
are detailed in Table  1. The median age was 64  years 
(range 1–93.8). Overall, the most common hemato-
logical disease was non-Hodgkin’s lymphoma (n = 91, 
25%) followed by plasma cell disorders (n = 81, 22%). As 
expected, patients who did not receive SCT were older, 
had been diagnosed more recently of their hematological 
malignancy and/or had received chemotherapy less than 
40 days before the SARS-CoV-2 infection, and thus they 
also had higher rates of uncontrolled hematological dis-
ease (not in partial or complete remission). Of note, they 
had higher comorbidities such as hypertension, cardio-
myopathy and dyslipidemia (p < 0.01 for all comparisons). 
In contrast, recipients of SCT had received more prior 
lines of therapy, while allo-SCT recipients were com-
monly receiving immunosuppressive drugs at the time of 
COVID-19 diagnosis (p < 0.01 for all comparisons).
Clinical characteristics of COVID‑19 in non‑transplant 
and transplant patients
Detailed clinical and laboratory characteristics of 
COVID-19 by patient category (non-SCT, ASCT and 
allo-SCT recipients) are shown in Table 2. Most patients 
(n = 250, 68%) were diagnosed from March 19th to April 
8th (see Fig.  1). Out of the 367 cases, 285 (78%) were 
diagnosed in the outpatient or emergency units, and 
non-SCT patients were more commonly diagnosed dur-
ing a hospital admission for treatment of their hemato-
logical disease or its complications (23% vs. 12% in SCT 
recipients).
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Table 1 Patient’s characteristics
SCT: stem cell transplantation; ASCT: autologous stem cell transplantation; allo-SCT: allogeneic hematopoietic stem cell transplantation; AML: acute myeloid 
leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; cMPD: chronic myeloproliferative disease; NHL: non-Hodgkin lymphoma; CLL: chronic 
lymphocytic leukemia; AA: aplastic anemia; CR: complete remission; PR: partial remission; Rel: relapse; Ref: refractory; Prog: progression; CNI: calcineurin inhibitors; 
MMF: mycophenolate mophetil acid; F/U: follow-up
Characteristics Hematological disease, 
non‑SCT (n = 244)
ASCT (n = 58) Allo‑SCT (n = 65) p value
Age (years), median (range) 71 (7–93) 61 (34–75) 48 (1–70) < 0.0001
 0–40 years, n (%) 20 (8) 1 (2) 25 (39) < 0.0001
 41–60 years, n (%) 51 (22) 22 (38) 21 (32)
 61–70 years, n (%) 45 (18) 30 (52) (17) (26)
 >71 years, n (%) 128 (52) 5 (8) 2 (3)
Male, n (%) 132 (54) 34 (59) 40 (61) 0.5
Baseline disease, n (%) < 0.0001
 AML 44 (19) 0 23 (35)
 ALL 12 (5) 1 (2) 12 (18)
 MDS 12 (5) 0 10 (15)
 CMPD 27 (11) 0 2 (3)
 NHL 68 (28) 17 (30) 6 (9)
 CLL 2 (10) 0 2 (3)
 Plasmatic cell disorder 40 (16) 38 (66) 3 (5)
 AA or auto‑immune disorders 13 (6) 1 (2) 5 (8)
Disease status, n (%) < 0.0001
 CR/PR 81 (33)/45 (18) 28 (48)/16 (28) 56 (86)/0
 Not in remission (Rel/Ref/Prog) 10 (4)/8 (3)/23 (9) 5 (8)/1 (2)/6 (10) 6 (9)/0/2 (3)
 Active disease not requiring therapy 22 (9) 0 0
Prior lines of therapy
 0–1 189 (77) 21 (36) 26 (40) < 0.001
 > 1 55 (23) 37 (64) 39 (60)
Allo‑SCT, n (%)
 HLA identical sibling 29 (45)
 Unrelated Donor 22 (34)
 Haplo‑identical family donor 14 (21)
Time from transplant to COVID‑19, days (range) 790 (10–10661) 441 (6–7597) 0.1
Prior therapy/conditioning 40 days before COVID‑19, n (%) 102 (42) 24 (41) 10 (15) < 0.0001
Disease diagnosed within 40 days of COVID‑19, n (%) 60 (25) 0 0 < 0.0001
Under immunosuppressive drugs before COVID‑19
 CNI or sirolimus or MMF 0 0 28 (43) < 0.0001
 Performance status, n (%) 0.2
 ECOG 0–1 166 (68) 48 (82) 50 (77)
 ECOG 2/ECOG 3–4 45 (18)/28 (11) 7 (12)/2 (3) 7 (11)/5 (8)
Pulmonary/cardiovascular risk factors, n (%)
 Active smoking 27 (11) 4 (7) 2 (3) 0.12
 Arterial hypertension 118 (48) 12 (21) 12 (18) < 0.0001
 Cardiomyopathy 51 (21) 10 (17) 4 (6) 0.021
 Dyslipidemia 78 (32) 11 (19) 5 (8) < 0.0001
 Diabetes 9 (4) 3 (5) 3 (5)
Median F/U after COVID‑19, days (range) 21 (0–74) 30 (0–72) 35 (0–72) 0.2
 Median F/U in survivors, days (range) 33 (10–74) 34 (11–72) 40 (12–72) 0.2
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Table 2 Clinical and laboratory characteristics
Characteristics Hematological disease, 
non‑SCT (n = 244)
ASCT (n = 58) Allo‑HCT (n = 65) p value
Place of SARS‑CoV‑2 infection, n (%) 0.1
 Outpatient 180 (74) 50 (86) 55 (85)
 Inpatient in specialized hospital 55 (23) 7 (12) 8 (12)
 Hospice institution 9 (4) 1 (2) 2 (3)
 COVID‑related hospital admission, n (%) 163 (67) 42 (72) 44 (68) 0.079
Symptoms, n (%)
 Asymptomatic 19 (8) 6 (10) 5 (8) 0.9
 Fever 178 (73) 40 (69) 41 (63) 0.6
 Rhinorrhea 29 (12) 11 (19) 14 (22) 0.3
 Pharyngitis 15 (6) 3 (5) 9 (14) 0.09
 Fatigue 140 (57) 24 (41) 32 (49) 0.25
 Myalgia 51 (21) 9 (16) 13 (20) 0.38
 Cough 175 (72) 30 (52) 39 (60) 0.069
 Diarrhea 54 (22) 15 (26) 12 (18) 0.5
 Emesis 23 (9) 8 (14) 6 (9) 0.46
COVID‑19  stagea, n (%)
 Stage 1 41 (17) 15 (26) 18 (28) 0.075
 Stage 2A 70 (29) 22 (38) 19 (29) 0.38
 Stage 2B 133 (55) 21 (36) 28 (43) 0.027
Oxygen support, n (%) 136 (56) 24 (41) 32 (49) 0.021
Abnormal radiological pulmonary finding, n (%) 200 (82) 44 (76) 46 (71) 0.35
Antiviral COVID‑19 therapy, n (%) 0.05
 None 49 (20) 16 (28) 13 (20)
 HCQ 15 (6) 0 11 (17)
 HCQ + AZT 36 (15) 5 (9) 8 (12)
 HCQ + AZT + lop/rit 14 (5) 3 (5) 1 (1)
 lop/rit 29 (12) 4 (9) 5 (8)
 HCQ + lop/rit 32 (13) 14 (24) 8 (12)
 AZT + lop/rit 39 (16) 6 (12) 8 (12)
 AZT 24 (10) 5 (7) 7 (11)
 Remdesivir 3 (1) 3 (5) 2 (3)
 Other 4 (2) 3 (5) 3 (5)
Corticosteroid therapy 0.029
 No 132 (54) 40 (69) 45 (69)
 ≤0.5 mg/kg/dayb 29 (12) 7 (12) 9 (14)
 >0.5 mg/kg/dayb 83 (34) 11 (19) 11 (17)
Anti‑cytokine supportive therapy, n (%)
 Tocilizumab 26 (11) 10 (17) 14 (21) 0.05
 Anakinra 10 (4) 3 (5) 5 (8)
 Baricitinib 6 (2) 1 (2) 0
Laboratory characteristics at the time of SARS‑CoV‑2 detection
 ANC < 0.5 × 109/L, n (%) 36 (15) 4 (7) 4 (6) 0.089
 ALC < 0.5 × 109/L, n (%) 99 (41) 22 (38) 19 (29) 0.27
Platelet count (×  109/L), median (range) 109 (1–1075) 127 (5–410) 115 (10–548) 0.4
 < 20 ×  109/L 28 (13) 2 (4) 4 (7)
 21–50 ×  109/L 27 (12) 7 (14) 9 (15)
 > 50 ×   109/L 166 (75) 42 (82) 46 (78)
CRP > 20 mg/dL (n/evaluable, %) 152/217 (70) 23/48 (48) 25/54 (46) 0.001
IL‑6 > 50 pg/mL (n/evaluable, %) 28/70 (40) 6/15 (40) 11/25 (44) 0.9
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During follow-up, 30 patients (8%) who were asymp-
tomatic at the time SARS-CoV-2 infection was made 
did not develop symptoms during follow-up (no dif-
ferences by patient type). Otherwise, the most com-
mon clinical features were fever (n = 259, 71%) cough 
(n = 244, 66%), fatigue (n = 192, 53%) and diarrhea 
(n = 81, 22%). COVID-19 was in stage I in 74 cases 
(20%), stage IIA in 111 patients (30%) and stage IIB in 
182 cases (50%). We did not observe significant varia-
tions in clinical symptoms among groups. Although 
pulmonary involvement was not significantly different 
amongst groups (83%, 74% and 72% of non-SCT, ASCT 
and allo-SCT, respectively, p = 0.2), non-SCT and allo-
SCT patients had higher rates of acute respiratory 
failure (stage IIB) than ASCT (55% vs. 48% vs. 36%, 
respectively, p = 0.027).
Regarding the available laboratory data, non-
SCT patients had higher rates of severe neutropenia 
(< 0.5 × 109/mL) and high CRP (> 20  mg/dL) as com-
pared to ASCT and allo-SCT (p < 0.0001), whereas high 
IL-6, ferritin and D-dimer levels were similar among 
groups, although these latter laboratory values were 
available in less than half of the patients (see Table 2).
Table 2 (continued)
Characteristics Hematological disease, 
non‑SCT (n = 244)
ASCT (n = 58) Allo‑HCT (n = 65) p value
Ferritin > 500 µg/mL, (n/evaluable, %) 80/104 (77) 14/21 (67) 25/29 (86) 0.4
D dimer > 500 ng/mL (n/evaluable, %) 127/197 (64) 20/42 (48) 25/46 (54) 0.085
Recovery from COVID‑19 (n/evaluable, %) 107/218 (49) 42/57 (74) 33/59 (56) 0.001
PCR negativity documented (n/evaluable, %) 49/131 (37) 15/30 (50) 13/27 (48) 0.01
Median time from diagnosis to negativity, days (range) 20 (4–48) 26 (7–53) 26 (7–43) 0.5
Overall mortality, n (%) 80 (33) 12 (21) 13 (20) 0.1
COVID‑19 related mortality, n (%) 76 (31) 10 (17) 12 (18) 0.02
Median time from diagnosis to death, days (range) 7.5 (0–38) 13 (0–51) 8 (0–42) 0.18
Admission to the ICU, n (%) 28 (11) 8 (14) 7 (11) 0.8
ICU mortality rate, n (%) 16 (57) 2 (25) 3 (43) 0.2
SCT: stem cell transplantation; ASCT: autologous stem cell transplantation; allo-SCT: allogeneic hematopoietic stem cell transplantation; HCQ: hydroxi-cloroquine; AZT: 
azithromycin; lop/rit, lopinavir/ritonavir; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; CRP: C-reactive protein; IL: interleukin; PCR: polymerase 
chain reaction; ICU: intensive care unit
a As suggested in Siddiqi et al. [15]
b  Refers to dose of IV methylprednisolone or an equivalent dose of another corticosteroid
Fig. 1 Number of cases and mortality rate according to the severity of COVID‑19 and the date of diagnostic
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Outcome and mortality
The overall median follow-up after SARS-CoV-2 infec-
tion was 25  days (range 0-74) for the entire cohort 
(see Table 1). At the time of the last follow-up, centers 
reported a higher proportion of full clinical recovery 
from COVID-19 in ASCT recipients (74%) as com-
pared to allo-SCT (56%) and non-SCT patients (48%) 
(p < 0.0001). The proportion of documented SARS-
CoV-2 PCR negativity during follow-up screening was 
also higher in SCT patients (ASCT 50% and allo-SCT 
48%) as compared to non-SCT (37%) (p = 0.01) with-
out any significant differences in time to negativity 
(see Table 2).
Overall mortality at day 45 after SARS-CoV-2 
detection was 29% (n = 105), whereas day 45 
COVID-19-related mortality was 27% (n = 98). The 
COVID-19-related mortality was higher in non-SCT 
(31%) as compared to ASCT (17%) and allo-SCT (18%) 
(p = 0.02). Median time to death was similar among 
groups (see Table  2). Overall mortality in patients 
who were considered suitable candidates for the ICU 
(n = 43) was high (n = 21, 49%) without differences 
between groups. Overall mortality rate according to 
the date of COVID-19 diagnosis is shown in Fig.  1. 
Overall mortality according to the COVID-19 stage 
in the entire cohort and by patient groups is shown in 
Fig. 2a–d.
Risk factors for severe COVID‑19 (stage IIB) and mortality
Logistic regression univariate and multivariate analy-
ses of conditions associated with COVID-19 stage IIB 
and related mortality in all 367 patients are shown in 
Table 3.
By multivariate analysis we identified 3 conditions 
associated with stage IIB or severe COVID-19; history of 
hypertension [Odds ratio (OR) 2, 95% confidence interval 
(CI) 1.3–3.2, p = 0.02], baseline lymphopenia (< 0.5 × 109/
mL) (OR 1.7, 95% CI 1.1–2.7, p = 0.015) and baseline 
CRP > 20 mg/dL (OR 2.67, 95% CI 1.6–4.3, p < 0.0001).
Finally, 5 conditions were associated with increased 
COVID-19-related mortality: (i) age > 70  years (OR 2.1, 
95% CI 1.2–3.8, p = 0.011); (ii) uncontrolled hemato-
logical disease (OR 2.9, 95% CI 1.6–5.2, p < 0.0001); (iii) 
ECOG 3–4 (OR, 2.56, 95% CI 1.4–4.7, p = 0.003); (iv) 
neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3–6.1, 
p = 0.01); and (v) CRP > 20 mg/dL (OR 3.3, 95% CI 1.7–
6.4, p < 0.0001). Mortality rates progressively increased 
according to the presence of 0–1, 2 or > 2 of these 5 RFs, 
as shown in Fig.  3a. Rising mortality by number of RFs 
was also observed in patients with stages IIA-IIB only, in 
patients with or without uncontrolled malignancy, and in 
non-SCT patients or SCT recipients (shown in Fig. 3b–f).
Effect of anti‑viral and anti‑cytokine supportive therapy 
on day 45 COVID‑19‑related mortality
Most patients (n = 289, 79%) received therapy against 
SARS-CoV-2, with azithromycin (n = 156, 42%) and 
hidroxycloroquine (n = 147, 40%) being the most com-
mon agents prescribed (details are shown in Table  2). 
However, each center established its own treatment algo-
rithms, which also probably varied on a patient by patient 
basis according to the stage and progression of COVID-
19. Unfortunately, we did not capture the exact date of 
start and end of these therapeutic interventions. Thus, in 
order to evaluate the potential effect of therapy, we per-
formed a second multivariate analysis of COVID-19-re-
lated mortality including only the 216 patients (59%) with 
very severe disease. Results of these univariate and multi-
variate analyses are shown in Table 4.
Treatments which led to lower mortality in multi-
variate analysis were (i) the use of azithromycin (OR 
0.42, 95% CI 0.2–0.89, p = 0.02), and (ii) the use of cor-
ticosteroids at doses ≤ 0.5  mg/kg/day (OR 0.31, 95% 
CI 0.11–0.87, p = 0.02); higher doses of corticosteroids 
(> 0.5  mg/kg/day) did not show any effect on mortal-
ity. Of note, the use of hidroxycloroquine did not show 
significant improvement in OM. Other variables asso-
ciated with higher mortality in this subset analysis of 
severely ill patients were; (iii) age > 70 years (OR 2.54, 95% 
CI 1.2–5.2, p = 0.011); (iv) uncontrolled hematological 
disease (OR 3.5, 95% CI 1.6–7.5, p = 0.001); (v) platelet 
count ≤ 20 × 109/L (OR, 5.66, 95% CI 1.44–22, p = 0.013); 
(vi) platelet count 21–0  × 109/L (OR 3.3, 95% CI 1.2–9.2, 
p = 0.021); (vii) history of arterial hypertension (OR, 2, 
95% CI 1.3–3.2, p = 0.002); and (viii) CRP > 20  mg/dL 
(OR 2.7, 95% CI 1.1–6.5, p = 0.029).
Discussion
We report herein a real-life experience with COVID-
19 diagnosed in a large number of Hematology units in 
Spain over a two-month period during the first pandemic 
wave of the SARS-CoV-2 infection. Our results show an 
overall mortality rate at day 45 after diagnosis of 29% 
(27% COVID-19-related according to the treating physi-
cians). Of note, a lower mortality was seen in recipients 
of a SCT (including allo-SCT recipients) as compared to 
non-SCT patients.
For its simplicity and the ability to classify cases into 
moderate or severe cases of pneumonia, we used the 
COVID-19 stages classification, as developed by Siddiqi 
et  al. [15], and as expected found that stage IIB (pneu-
monia with acute respiratory failure) significantly cor-
related with higher mortality (shown in different study 
groups in Fig.  1a–d). This easy-to-implement classifica-
tion could be of value for future observational studies 
and for the design of future randomized clinical trials. 
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Additionally, we found that hypertension, lymphopenia 
and high CRP predicted for the development of stage IIB 
COVID-19. Although hypertension and lymphopenia 
were not found to independently increase mortality in 
our study, both variables have been shown to be strong 
predictors of mortality in the general population and we 
can thus postulate that with larger patient numbers they 
would also have had an impact on survival. On the other 
hand, higher mortality was linked with age > 70  years, 
uncontrolled hematological malignancy, baseline poor 
Fig. 2 Day 45 overall mortality. a In the entire cohort, according to the COVID‑19 stage, mortality was 8% in patients with stage I, 18% in those 
with stage IIA and 53% in those who evolved to stage IIB ((p < 0.0001). b Mortality rate in non‑SCT patients was 10% vs. 23% vs. 53% in patients with 
stage I, stage IIA and Stage IIB, respectively (p < 0.0001). c Mortality in autologous SCT recipients was 13%, 11% and 50% in patients with stage I, 
stage IIA and Stage IIB, respectively (p < 0.09). d Mortality in allo‑SCT recipients was 0%, 17% and 47% in patients with stage I, stage IIA and Stage IIB, 
respectively (p < 0.01)
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Table 3 Univariate and multivariate analysis of risk factors for stage IIB COVID-19 and COVID-19-related mortality
SCT: stem cell transplantation; ASCT: autologous stem cell transplantation; allo-SCT: allogeneic hematopoietic stem cell transplantation; AML: acute myeloid 
leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; cMPD: chronic myeloproliferative disease; NHL: non-Hodgkin lymphoma; CLL: chronic 
lymphocytic leukemia; AA: aplastic anemia; CR: complete remission; PR: partial remission; Rel: relapse; Ref: refractory; Prog: progression; Dx: diagnostic; ANC: absolute 
neutrophil count; ALC: absolute lymphocyte count; CRP: C-reactive protein; IL: interleukin; ns: not significant; NT: not tested
a Stage IIB refers to severe disease, with pulmonary involvement and acute respiratory failure, as suggested in Siddiqi et al. [15]
b These variables were not included in the multivariate analyses due to the low number of patients with complete data
Variables Log. Regr. COVID‑19 Stage II  Ba (n = 367) Log. Regr. COVID‑19 Mortality (n = 367)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p OR (95% CI) p R (95% CI) p value
Patient age > 70 years old 2.25 (1.45–3.5) < 0.0001 ns 3.1 (1.9–5) < 0.0001 2.1 (1.2–3.8) 0.011
Patient age ns ns
 0–20 1 1
 21–70 5.6 (1.2–25) 0.02 0.7 (0.22–2.3) 0.59
 >70 11.5 (2.5–52) 0.002 2.3 (0.7–7.5) 0.16
Sex male 1.41 (0.93–2.1) 0.09 ns 0.95 (0.6–1.5) 0.8
Baseline disease ns ns
 AML 1 1
 ALL 0.8 (0.3–2) 0.68 0.6 (0.22–1.67) 0.3
 MDS 1.3 (0.5–3.4) 0.5 0.69 (0.25–1.9) 0.47
 CMPD 2.7 (1.1–6.8) 0.032 0.6 (0.23–1.5) 0.3
 NHL 1.37 (0.7–2.6) 0.3 0.63 (0.3–1.2) 0.3
 CLL 2.9 (1.12–7.6) 0.03 0.7 (0.35–1.06) 0.06
 Plasmatic cell disorder 0.98 (0.5–1.8) 0.9 0.7 (0.35–1.4) 0.3
 AA or auto‑immune disorders 0.3 (0.09–1.1) 0.07 0.08 (0.01–0.69) 0.02
Disease status ns
 CR/PR/not requiring therapy 1 1
 Rel/Ref/Prog 1.49 (0.96–2.3) 0.076 3.78 (2.3–6) < 0.0001 2.9 (1.6–5.2) < 0.0001
Procedure ns ns
 Allo‑SCT 1 1
 ASCT 0.75 (0.37–1.5) 0.4 1.04 (0.43–2.5) 0.9
 Non‑SCT 1.57 (0.92–2.6) 0.09 1.95 (1.03–3.7) 0.048 ns
Chemotherapy 40 days before COVID‑19 1.18 (0.7–1.8) 0.4 ns 1.76 (1.1–2.79) 0.016 ns
Disease Dx within 40 days of COVID‑19 1.1 (0.6–1.9) 0.7 ns 2.2 (1.24–3.9) 0.007 ns
ECOG 3–4 1.8 (1.14–2.98) 0.012 ns 3.7 (2.2–6.1) < 0.0001 2.56 (1.4–4.7) 0.003
Active smoking 1.88 (0.89–3.9) 0.094 ns 1.3 (0.6–2.79) 0.4
Arterial hypertension 2.26 (1.4–3.49) < 0.0001 2 (1.3–3.2) 0.002 2.6 (1.6–4.16) < 0.0001 ns
Cardiomyopathy 1.98 (1.1–3.4) 0.015 ns 1.6 (0.9–2.88) 0.089 ns
Dyslipidemia 1.6 (1–2.59) 0.049 ns 1.86 (1.1–3) 0.015 ns
Place of SARS‑CoV‑2 infection ns
 Outpatient 1 1
 Inpatient in specialized hospital 1.1 (0.6–1.8) 0.69 1.05 (0.3–3.6) 0.9
ALC < 0.5 × 109/L 1.7 (1.1–2.68) 0.014 1.7 (1.1–2.7) 0.015 2.25 (1.6–3.6) 0.001 ns
ANC < 0.5 × 109/L 1.4 (0.7–2.7) 0.27 ns 3.4 (1.8–6.67) < 0.0001 2.8 (1.3–6.1) 0.01
Platelet count (×  109/L) ns
 < 20 ×  109/L 1.7 (0.8–3.66) 0.16 4.44 (2.1–9.4) < 0.0001
 21–50 ×  109/L 1.18 (0.6–2.26) 0.6 3.6 (1.8–7.05) < 0.0001
 > 50 ×  109/L 1 1
CRP > 20 mg/dL 3.1 (1.9–4.9) < 0.0001 2.67 (1.6–4.3) < 0.0001 4 (2.2–7.18) < 0.0001 3.3 (1.7–6.4) < 0.0001
IL‑6 > 50 pg/mLb 3.2 (1.38–7.35) 0.007 NT 2.7 (1.1–6.59) 0.028 NT
Ferritin  levelsb NT NT
 <500 µg/mL 1 1
 501–1000 µg/mL 1.18 (0.4–3.2) 1 (0.24–4.1) 0.99
 >1001 µg/mL 2.4 (1.1–5.35) 0.03 2.8 (1–7.9) 0.05
D dimer > 500 ng/mLb 1.6 (1.02–2.6) 0.04 NT 1.34 (0.8–2.3) 0.2 NT
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performance status, baseline severe neutropenia and a 
high CRP. With these RFs, we built a simple prognostic 
score based on the presence of 0–1, 2 or > 2 RFs, which 
clearly segregated the day 45 mortality into 3 groups. 
This segregation was obvious in the overall population 
[low risk (18% mortality), moderate risk (35% mortality) 
and high-risk (54% mortality); Fig.  2a], and also when 
tested separately in patients with pneumonia (Fig.  2b), 
in patients with uncontrolled or controlled underly-
ing disease (Figs. 2c, d) and in SCT recipients as well as 
non-SCT patients (Fig.  2e, f ). The lowest mortality was 
observed in patients with controlled hematological dis-
ease and without RFs (7%) in contrast to that observed 
in patients with uncontrolled hematological disease 
with > 2 RFs (80%). Of course, as with any risk score 
obtained form a single study, its validation and improve-
ment in independent patient cohorts is required before 
one can suggest that it should be used to better predict 
the outcome of COVID-19 in patients with hematologi-
cal malignancies.
Characteristics of COVID-19 symptoms in hematologi-
cal patients share similarities with the general population 
[20], with fever, dry cough, fatigue and diarrhea being 
the most common initial signs/symptoms of infection. 
Systemic symptoms, however, were more common than 
URTD symptoms, as has also been reported in the gen-
eral population. Compared to non-immunosuppressed 
patients [3], SARS-CoV-2 shedding in the upper airway 
seemed longer in our series (median of 24  days) with 
long-lasting shedding (> 21  days) in a significant pro-
portion of studied cases (55%). The immunodeficiency 
driven by hematological malignancies and/or their treat-
ment may explain a longer time for virus clearance. In 
the general population, low circulating B cell counts 
have been correlated with prolonged viral shedding [21]. 
In spite of the immunosuppressed status, the propor-
tion of asymptomatic patients (8%) in our cohort was 
not irrelevant. Although our study was not designed to 
identify asymptomatic SARS-CoV-2 infections in our 
patients, it is obvious that these do exist, even if possibly 
at a lower rate than in the general population (reported 
to be approximately 30% of all infections) [22–26]. These 
observations support the recommendations for screening 
of SARS-CoV-2 infection in asymptomatic hematological 
patients before any scheduled treatments, including a 
planned SCT procedure, at least while the incidence in 
the community remains high.
In contrast with infections by other CARVs in hema-
tological patients [27], the proportion of patients who 
develop LRTD when infected by SARS-CoV-2 appeared 
to be very high (79%), albeit this propensity for causing 
pneumonia has been well described in the general popu-
lation [3]. In fact, the RFs we found for the development 
of severe COVID-19 pneumonia (stage IIB) were similar 
to those reported in the general population [3]. Hyper-
tension [3, 4, 28, 29], lymphopenia [30–33] and high 
blood levels of markers of inflammation (including CRP) 
[34–36] are among these reported RFs. Due to the lack of 
data in up to half of our patients, we were unable to ana-
lyze the impact of other inflammatory/procoagulant bio-
markers, such as ferritin, IL-6 and D-dimer on the risk of 
developing severe pneumonia and death, although they 
did show a clear trend in univariate analysis (as shown in 
Table 2).
The day 45 overall and COVID-19-related mortality in 
this series (29% and 27%, respectively) was comparable 
to other series of hematological patients [10–12], appar-
ently higher than patients with solid tumors (13%) [37] 
and much higher than in the general population (2.3%) 
[38]. Somewhat surprising, however, was the lower 
mortality observed in SCT recipients, a patient group 
usually linked to the highest risk of death from oppor-
tunistic infections, including those caused by other 
CARV. However, patients who receive a SCT, especially 
an allo-SCT, are by definition younger and healthier than 
the overall onco-hematological patients. In fact, in our 
cohort we observed that most of conditions associated 
with higher overall mortality in multivariate analysis 
(i.e. older age, hypertension, uncontrolled hematologi-
cal disease and high levels of CRP) were overrepresented 
in the non-SCT cohort, which may explain in part the 
lower mortality observed in SCT recipients. The fact 
that all patients with hematological malignancies were 
registered in the current study, without the strict inclu-
sion criteria used in prospective treatment protocols 
and, especially, in clinical trials and for receiving a SCT, 
creates a much more real-life scenario. Indeed, clini-
cians are well accustomed to seeing elderly patients with 
(See figure on next page.)
Fig. 3 COVID‑19‑related mortality according to the presence of 0‑1, 2 and > 2 risk factors. a In the entire cohort. Mortality rate was 18% vs. 35% 
vs. 54%, respectively (p < 0.0001). b In patients with lower respiratory involvement (stages IIA and IIB), the mortality was 22% vs. 40% vs. 58%, 
respectively (p < 0.0001). c In patients with uncontrolled hematological malignancy at the time of COVID‑19 the mortality was 33% vs. 63% vs. 
80%, respectively (p < 0.0001). d In patients with controlled hematological disease at the time of COVID‑19 the mortality was 7% vs. 22% vs. 44%, 
respectively (p < 0.0001). e In stem cell transplant (SCT) recipients the mortality was 17% vs. 34% vs. 56%, respectively (p < 0.0001). f In non‑stem cell 
transplant (SCT) patients the mortality was 19% vs. 34% vs. 54%, respectively (p < 0.0001)
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Table 4 Univariate and multivariate analysis of risk factors for COVID-19-related mortality in patients with very severe 
COVID-19
Variables Log. Regr. COVID‑19 Mortality in patients with COVID‑19 > stage IIA (n = 216)
Univariate analysis Multivariate analysis
OR (95% CI) % (95%CI) p OR (95% CI) p
Patient age > 70 years old 2.5 (1.4–4.3) 0.001 2.54 (1.2–5.2) 0.011
Patient age ns
 0–20 1
 21–70 0.15 (0.017–1.4) 0.11
 > 70 0.45 (0.04–3.9) 0.4
Sex male 1.2 (0.43–1.3) 0.3
Baseline disease ns
 AML 1
 ALL 0.5 (0.13–1.9) 0.31
 MDS 0.48 (0.11–1.4) 0.15
 CMPD 0.25 (0.08–0.76) 0.014
 NHL 0.3 (0.12–0.73) 0.008
 CLL 0.11 (0.03–0.41) 0.001
 Plasmatic cell disorder 0.5 (0.2–1.3) 0.18
 AA or auto‑immune disorders 0.09 (0.09–0.89) 0.04
Disease status
 CR/PR/not requiring therapy 1
 Rel/Ref/Prog 4.3 (2.388–7.8) < 0.0001 3.5 (1.6–7.5) 0.001
Procedure
 Allo‑SCT 1
 ASCT 1.08 (0.38–3) 0.8
 Non‑SCT 1.58 (0.74–3.3) 0.23
Chemotherapy 40 days before COVID‑19 1.56 (0.9–2.7) 0.11
Disease Dx within 40 days of COVID‑19 3.5 (1.56–7.8) 0.002 ns
ECOG 3–4 3.1 (1.7–5.76) < 0.0001 ns
Active smoking 0.88 (0.37–2.1) 0.8
Arterial hypertension 1.97 (1.14–.4) 0.014 2 (1.3–3.2) 0.002
Cardiomyopathy 1.21 (0.6–2.36) 0.56
Dyslipidemia 1.4 (0.8.–2.6) 0.2
ALC < 0.5 × 109/L 1.7 (1–3) 0.05 ns
ANC < 0.5 × 109/L 3.7 (1.58–8.7) 0.002 ns
Specific therapy
 HCQ 0.64 (0.37–1.1) 0.1 ns
 AZT 0.49 (0.28–0.84) 0.01 0.42 (0.2–0.89) 0.02
 HCQ +AZT 0.6 (0.3–1.2) 0.14
 lop/rit 0.7 (0.4–1.2) 0.2
 Remdesivir 0.18 (0.02–1.6) 0.12
Corticosteroid therapy 0.54 (0.31–0.93) 0.028 ns
Corticosteroid doses
 No 1 1
 ≤0.5 mg/kg/dayb 0.44 (0.23–0.83) 0.014 0.31 (0.11–0.87) 0.02
 >0.5 mg/kg/dayb 0.54 (0.27–1.06) 0.075 0.75 (0.34–1.6) 0.4
Cytokine inhibitors 0.6 (0.34–1.1) 0.16
Tocilizumab 0.54 (0.28–1.05) 0.073 ns
Platelet count (×  109/L)
 ≤ 20 ×  109/L 6.4 (2–19) 0.001 5.66 (1.44–22) 0.013
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many comorbidities who are far from being candidates 
to the standard-of-care for their AML, MDS, lymphoma, 
myeloma and other diseases, and patient-specific treat-
ment decisions must commonly be made. In such real-
life setting, COVID-19 mortality was mainly driven by 
advanced age, poor performance status, uncontrolled 
disease status (not being at least in a partial remission), 
presence of marrow or immune failure (severe neutro-
penia, and lymphopenia in the univariate analysis) and 
having a high baseline and/or COVID-19 induced sys-
temic inflammatory state (identified in the multivariate 
analysis by high CRP, although high levels of IL-6 and 
ferritin showed a strong trend in univariate analysis). In 
contrast, the broad range of hematological malignan-
cies included did not allow us to study the impact of this 
infection in different diagnoses.
We decided to evaluate the effect of several treatments 
on mortality only in patients who developed very severe 
COVID-19 and found that having received azithromycin 
(AZT) or low-dose corticosteroids were independently 
associated with lower mortality. Obviously, many clini-
cians have been using macrolides to treat COVID-19 
off-label, without any robust evidence of safety or effec-
tiveness. Our results suggest that the use of azithromy-
cin at least did not have a deleterious impact on survival. 
In contrast, we found no impact of using hydroxychlo-
roquine (HCQ). To what extend the lack of its benefit 
could be related to potential severe toxicities or insuf-
ficient antiviral activity remains to be determined [39]. 
Regarding the use of short courses of corticosteroids 
for COVID-19, prior reports have yielded conflicting 
results; both favorable [40–43] and detrimental effects 
[44, 45] have been found. A preliminary, unpublished 
analysis from a large, multicenter, randomized, open-
label trial (RECOVERY study) showed that dexametha-
sone at 6  mg/day for 10  days reduced the mortality in 
patients with severe COVID-19 (defined as those who 
required supplemental oxygen) [46]. Our findings are 
in line with results from this trial, since 6  mg of dexa-
methasone is equivalent to 40 mgr of oral prednisone 
or 32 mgr of IV methylprednisolone, and the latter is 
within our definition of low-dose steroids (≤ 0.5 mg/kg/
day methylprednisolone). However, our results should 
be interpreted with great caution and should not be used 
to support the use of either azithromycin or low-dose 
steroids in patients with hematological malignancies. 
Management of COVID-19 is a worldwide research pri-
ority, and the optimal treatment of our patients must be 
guided by the results of these international randomized 
clinical trials.
We acknowledge several limitations of this study such 
as its retrospective nature, the use of different PCR assays 
and the lack of complete inflammatory markers data in 
most cases. However, the large number of patients and 
the comparison between non-SCT and SCT recipients 
should be considered as its strengths, and a starting point 
for future larger and more disease-specific or treatment-
specific observational studies. Additionally, our hemato-
logical COVID-19 database (see Fig. 1) mirrored national 
epidemiological data in SARS-CoV-2 during each week 
[47]. This fact suggests a low probability of bias in report-
ing hematological COVID-19 cases in our study.
SCT: stem cell transplantation; ASCT: autologous stem cell transplantation; allo-SCT: allogeneic hematopoietic stem cell transplantation; AML: acute myeloid 
leukemia; ALL: acute lymphoblastic leukemia; MDS; myelodysplastic syndrome; cMPD: chronic myeloproliferative disease; NHL: non-Hodgkin lymphoma; CLL: chronic 
lymphocytic leukemia; AA: aplastic anemia; CR: complete remission; PR: partial remission; Rel: relapse; Ref: refractory; Prog: progression; Dx: diagnostic; ANC: absolute 
neutrophil count; ALC: absolute lymphocyte count; HCQ: hydroxi-cloroquine; AZT: azithromycin; lop/rit: lopinavir/ritonavir; CRP: C-reactive protein; IL: interleukin; ns: 
not significant; NT: not tested
a These variables were not included in the multivariate analyses due to the low number of patients with complete data
b Refers to dose of IV methylprednisolone or an equivalent dose of another corticosteroid
Table 4 (continued)
Variables Log. Regr. COVID‑19 Mortality in patients with COVID‑19 > stage IIA (n = 216)
Univariate analysis Multivariate analysis
OR (95% CI) % (95%CI) p OR (95% CI) p
 21–50 ×  109/L 4.1 (1.7–9.7) 0.001 3.3 (1.2–9.2) 0.021
 > 50 ×  109/L 1 1
CRP > 20 mg/dL 2.1 (1.08–4.1) 0.027 2.7 (1.1–6.5) 0.029
IL‑6 > 50 pg/mLa 1.8 (0.69–4.7) 0.2 NT
Ferritin  levelsa NT
 <500 µg/mL 1
 501–1000 µg/mL 0.9 (0.2–4.3) 0.9
 >1001 µg/mL 2.2 (0.72–7) 0.15
 D dimer > 500 ng/mLa 1.39 (0.76–2.6) 0.2 NT
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Conclusions
COVID-19 was severe in patients with hematological 
malignancies, and their survival was strongly correlated 
with the COVID-19 stage and patient and disease-related 
factors [older age, disease status, performance status, 
immune (neutropenia) status and systemic inflammation 
(high CRP)]. However, recipients of a SCT did not have a 
higher mortality.
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